Parkinson’s disease is unique to every patient, and people living with it can have a difficult time finding a treatment regimen to help them best manage side effects. Research for a cure remains a priority in the medical community, and the volunteers at Connecticut Advocates for Parkinson’s in Windsor are excited to share information about the recent approval of a new drug. PWP’s know that Parkinson’s  can be extremely difficult to manage, and while other medications have helped patients in the past, this option advances one step closer to finding a cure.

Insight Into the New Drug

The medication—Osmolex ER™ (amantadine extended-release)—was recently approved by the FDA. It focuses on managing debilitating Parkinson’s disease symptoms such as tremor and uncontrolled or involuntary movements. Developed by Osmotica Pharmaceutical US LLC, Osmolex ER is unlike other Parkinson’s drugs, in that it only needs to be taken once each day. By using a combination of immediate and extended-release amantadine—the primary compound in the medication—it becomes much easier for patients to handle. It comes in three doses: 129 mg, 193 mg, and 258 mg tablets, and is designed to be highly customizable for patients.

Switching to Osmolex ER

Treating Parkinson’s disease is extremely complicated, and many patients have difficulty tolerating or responding positively to different medications. With Osmolex ER, patients now have a new option to try alongside therapy and complementary treatments. If you’re interested in exploring Osmolex ER, speak with your primary care physician so they can determine if it’s the best course for you.

The volunteers at Connecticut Advocates for Parkinson’s work to ensure that people living with Parkinson’s disease and their families can enjoy healthy, fulfilling lives. They offer a variety of services and resources all geared toward supporting Parkinson’s research and care. If you’re interested in learning more, call (860) 266-6040 today. You can also visit their website and Facebook for the latest news, directories to clinical trials, and other helpful information.